[시장보고서]증식성 당뇨망막병증 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

증식성 당뇨망막병증 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)

Proliferative Diabetic Retinopathy Market (Drug Class: Anti-VEGF Agents and Corticosteroids; and Mode of Administration: Injectable, Oral, and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2023-2031

상품코드 : 1442859

리서치사 : Transparency Market Research

발행일 : 2024년 01월

페이지 정보 : 영문 170 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,600,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 13,053,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 17,506,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

증식성 당뇨망막병증 시장 - 리포트 대상 범위

세계의 증식성 당뇨망막병증 시장에 관한 TMR의 리포트에서는 과거와 현재의 성장 동향 및 2023-2031년의 예측 기간 중 시장 지표의 귀중한 인사이트를 얻을 기회를 조사하고 있습니다. 이 리포트는 세계의 증식성 당뇨망막병증 시장의 2017-2031년 기간의 매출을 제공하고, 2023년을 기준년, 2031년을 예측년으로 간주합니다. 또한 2023-2031년 세계 증식성 당뇨망막병증 시장의 연평균 성장률(CAGR %)도 제공하고 있습니다.

이 리포트는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서는 조사 활동의 대부분을 시행하고 애널리스트가 주요 오피니언 리더, 업계 리더, 오피니언 제조업체와 인터뷰를 진행했습니다. 2차 조사에는 증식성 당뇨망막병증 시장을 이해하기 위해 주요 기업의 제품 문헌, 연차보고서, 프레스 릴리스 및 관련 문서의 참조가 포함됩니다.

이 리포트는 세계의 증식성 당뇨망막병증 시장의 경쟁 구도를 자세하게 조사하고 있습니다. 세계의 증식성 당뇨망막병증 시장에서 활동하는 주요 기업이 식별되고 각각의 기업이 다양한 속성의 관점에서 프로파일링되고 있습니다. 회사 개요, 재무 상황, 최근 동향, SWOT는 이 리포트에서 소개되고 있는 세계의 증식성 당뇨망막병증 시장 기업의 속성입니다.

시장 기업 : 경쟁 매트릭스(기업 계층·규모별)
시장 점유율 분석 : 기업별(2022년)
기업 개요
- Genentech, Inc.
- Novartis AG
- Regeneron Pharmaceuticals, Inc.
- Pfizer Inc.
- Merck KGaA
- Cipla Inc.
- AbbVie Inc.
- Bausch Health Companies Inc.
- Santen Pharmaceutical Co., Ltd.
- Alimera Sciences
- Intas Pharmaceuticals Ltd.

KSA

영문 목차

영문목차

Proliferative Diabetic Retinopathy Market - Scope of Report

TMR's report on the global proliferative diabetic retinopathy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global proliferative diabetic retinopathy market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global proliferative diabetic retinopathy market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the proliferative diabetic retinopathy market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global proliferative diabetic retinopathy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global proliferative diabetic retinopathy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global proliferative diabetic retinopathy market.

The report delves into the competitive landscape of the global proliferative diabetic retinopathy market. Key players operating in the global proliferative diabetic retinopathy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global proliferative diabetic retinopathy market profiled in this report.

Key Questions Answered in Global proliferative diabetic retinopathy Market Report:

What is the sales/revenue generated by proliferative diabetic retinopathy across all regions during the forecast period?
What are the opportunities in the global proliferative diabetic retinopathy market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Proliferative Diabetic Retinopathy Market - Research Objectives and Research Approach

The comprehensive report on the global proliferative diabetic retinopathy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global proliferative diabetic retinopathy market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global proliferative diabetic retinopathy market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Proliferative Diabetic Retinopathy Market

4. Market Overview

4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, 2017-2031

5. Key Insights

5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Drug Class

6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017-2031
- 6.3.1. Anti-VEGF Agents
- 6.3.2. Corticosteroids
6.4. Market Attractiveness Analysis, by Drug Class

7. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Mode of Administration

7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Mode of Administration, 2017-2031
- 7.3.1. Injectable
- 7.3.2. Oral
- 7.3.3. Others
7.4. Market Attractiveness Analysis, by Mode of Administration

8. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Distribution Channel

8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 8.3.1. Hospital Pharmacies
- 8.3.2. Retail Pharmacies
- 8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Region

9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Proliferative Diabetic Retinopathy Market Analysis and Forecast

10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2017-2031
- 10.3.1. Anti-VEGF Agents
- 10.3.2. Corticosteroids
10.4. Market Value Forecast, by Mode of Administration, 2017-2031
- 10.4.1. Injectable
- 10.4.2. Oral
- 10.4.3. Others
10.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 10.5.1. Hospital Pharmacies
- 10.5.2. Retail Pharmacies
- 10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2017-2031
- 10.6.1. U.S.
- 10.6.2. Canada
10.7. Market Attractiveness Analysis
- 10.7.1. By Drug Class
- 10.7.2. By Mode of Administration
- 10.7.3. By Distribution Channel
- 10.7.4. By Country

11. Europe Proliferative Diabetic Retinopathy Market Analysis and Forecast

11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2017-2031
- 11.3.1. Anti-VEGF Agents
- 11.3.2. Corticosteroids
11.4. Market Value Forecast, by Mode of Administration, 2017-2031
- 11.4.1. Injectable
- 11.4.2. Oral
- 11.4.3. Others
11.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 11.5.1. Hospital Pharmacies
- 11.5.2. Retail Pharmacies
- 11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.6.1. Germany
- 11.6.2. U.K.
- 11.6.3. France
- 11.6.4. Italy
- 11.6.5. Spain
- 11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
- 11.7.1. By Drug Class
- 11.7.2. By Mode of Administration
- 11.7.3. By Distribution Channel
- 11.7.4. By Country/Sub-region

12. Asia Pacific Proliferative Diabetic Retinopathy Market Analysis and Forecast

12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2017-2031
- 12.3.1. Anti-VEGF Agents
- 12.3.2. Corticosteroids
12.4. Market Value Forecast, by Mode of Administration, 2017-2031
- 12.4.1. Injectable
- 12.4.2. Oral
- 12.4.3. Others
12.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 12.5.1. Hospital Pharmacies
- 12.5.2. Retail Pharmacies
- 12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.6.1. China
- 12.6.2. Japan
- 12.6.3. India
- 12.6.4. Australia & New Zealand
- 12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
- 12.7.1. By Drug Class
- 12.7.2. By Mode of Administration
- 12.7.3. By Distribution Channel
- 12.7.4. By Country/Sub-region

13. Latin America Proliferative Diabetic Retinopathy Market Analysis and Forecast

13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2017-2031
- 13.3.1. Anti-VEGF Agents
- 13.3.2. Corticosteroids
13.4. Market Value Forecast, by Mode of Administration, 2017-2031
- 13.4.1. Injectable
- 13.4.2. Oral
- 13.4.3. Others
13.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 13.5.1. Hospital Pharmacies
- 13.5.2. Retail Pharmacies
- 13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.6.1. Brazil
- 13.6.2. Mexico
- 13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
- 13.7.1. By Drug Class
- 13.7.2. By Mode of Administration
- 13.7.3. By Distribution Channel
- 13.7.4. By Country/Sub-region

14. Middle East & Africa Proliferative Diabetic Retinopathy Market Analysis and Forecast

14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2017-2031
- 14.3.1. Anti-VEGF Agents
- 14.3.2. Corticosteroids
14.4. Market Value Forecast, by Mode of Administration, 2017-2031
- 14.4.1. Injectable
- 14.4.2. Oral
- 14.4.3. Others
14.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 14.5.1. Hospital Pharmacies
- 14.5.2. Retail Pharmacies
- 14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.6.1. GCC Countries
- 14.6.2. South Africa
- 14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
- 14.7.1. By Drug Class
- 14.7.2. By Mode of Administration
- 14.7.3. By Distribution Channel
- 14.7.4. By Country/Sub-region

15. Competition Landscape

15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
- 15.3.1. Genentech, Inc.
  - 15.3.1.1. Company Overview
  - 15.3.1.2. Product Portfolio
  - 15.3.1.3. SWOT Analysis
  - 15.3.1.4. Financial Overview
  - 15.3.1.5. Strategic Overview
- 15.3.2. Novartis AG
  - 15.3.2.1. Company Overview
  - 15.3.2.2. Product Portfolio
  - 15.3.2.3. SWOT Analysis
  - 15.3.2.4. Financial Overview
  - 15.3.2.5. Strategic Overview
- 15.3.3. Regeneron Pharmaceuticals, Inc.
  - 15.3.3.1. Company Overview
  - 15.3.3.2. Product Portfolio
  - 15.3.3.3. SWOT Analysis
  - 15.3.3.4. Financial Overview
  - 15.3.3.5. Strategic Overview
- 15.3.4. Pfizer Inc.
  - 15.3.4.1. Company Overview
  - 15.3.4.2. Product Portfolio
  - 15.3.4.3. SWOT Analysis
  - 15.3.4.4. Financial Overview
  - 15.3.4.5. Strategic Overview
- 15.3.5. Merck KGaA
  - 15.3.5.1. Company Overview
  - 15.3.5.2. Product Portfolio
  - 15.3.5.3. SWOT Analysis
  - 15.3.5.4. Financial Overview
  - 15.3.5.5. Strategic Overview
- 15.3.6. Cipla Inc.
  - 15.3.6.1. Company Overview
  - 15.3.6.2. Product Portfolio
  - 15.3.6.3. SWOT Analysis
  - 15.3.6.4. Financial Overview
  - 15.3.6.5. Strategic Overview
- 15.3.7. AbbVie Inc.
  - 15.3.7.1. Company Overview
  - 15.3.7.2. Product Portfolio
  - 15.3.7.3. SWOT Analysis
  - 15.3.7.4. Financial Overview
  - 15.3.7.5. Strategic Overview
- 15.3.8. Bausch Health Companies Inc.
  - 15.3.8.1. Company Overview
  - 15.3.8.2. Product Portfolio
  - 15.3.8.3. SWOT Analysis
  - 15.3.8.4. Financial Overview
  - 15.3.8.5. Strategic Overview
- 15.3.9. Santen Pharmaceutical Co., Ltd.
  - 15.3.9.1. Company Overview
  - 15.3.9.2. Product Portfolio
  - 15.3.9.3. SWOT Analysis
  - 15.3.9.4. Financial Overview
  - 15.3.9.5. Strategic Overview
- 15.3.10. Alimera Sciences
  - 15.3.10.1. Company Overview
  - 15.3.10.2. Product Portfolio
  - 15.3.10.3. SWOT Analysis
  - 15.3.10.4. Financial Overview
  - 15.3.10.5. Strategic Overview
- 15.3.11. Intas Pharmaceuticals Ltd.
  - 15.3.11.1. Company Overview
  - 15.3.11.2. Product Portfolio
  - 15.3.11.3. SWOT Analysis
  - 15.3.11.4. Financial Overview
  - 15.3.11.5. Strategic Overview

한글목차

증식성 당뇨망막병증 시장 - 리포트 대상 범위

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

제5장 주요 인사이트

제6장 세계 시장의 분석과 예측 : 약제 클래스별

제7장 세계 시장의 분석과 예측 : 투여 방법별

제8장 세계 시장의 분석과 예측 : 유통 채널별

제9장 세계 시장의 분석과 예측 : 지역별

제10장 북미 시장 분석과 예측

제11장 유럽 시장 분석과 예측

제12장 아시아태평양 시장 분석과 예측

제13장 라틴아메리카 시장 분석과 예측

제14장 중동 및 아프리카 시장 분석과 예측

제15장 경쟁 구도